Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    ponatinib
Show Display Options
Rank Status Study
1 Active, not recruiting Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib
Condition: Leukemia
Intervention: Drug: Ponatinib
2 Not yet recruiting Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   FLT3-Mutated Acute Myeloid Leukemia;   FLT3-Mutated High-Risk Myelodysplastic Syndrome
Interventions: Drug: Ponatinib;   Drug: 5-azacytidine;   Behavioral: Phone Calls
3 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
4 Recruiting Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
Condition: Acute Myeloid Lukemia
Intervention: Drug: Ponatinib and Cytarabine
5 Terminated
Has Results
Ponatinib for Squamous Cell Lung and Head and Neck Cancers
Condition: Non-Small Cell Lung Cancer, Head and Neck Cancer
Intervention: Drug: ponatinib
6 Recruiting Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Condition: Myeloid Leukemia, Chronic, Chronic Phase
Interventions: Drug: ponatinib 45 mg;   Drug: ponatinib 30 mg;   Drug: ponatinib 15 mg
7 Terminated Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Condition: Leukemia
Intervention: Drug: Ponatinib
8 Withdrawn Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Condition: Endometrial Neoplasms
Intervention: Drug: Ponatinib
9 Active, not recruiting A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions: Drug: ponatinib - Phase 1;   Drug: ponatinib - Phase 2
10 Recruiting Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Conditions: Adenocarcinoma of the Lung;   Extensive Stage Small Cell Lung Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Ponatinib
11 Approved for marketing Expanded Access Program of Ponatinib
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib
12 Not yet recruiting Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
Condition: ALL
Interventions: Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Ponatinib;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: VP-16;   Drug: ARA-C:;   Drug: TIT;   Procedure: Autologous transplantation;   Procedure: Allo transplantation
13 Recruiting Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Condition: Malignant Neoplasm
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
14 Recruiting Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
15 Recruiting Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Chronic Phase;   Adults
Intervention: Drug: Ponatinib
16 Active, not recruiting PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Ph+ Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Ponatinib 45 mg QD
17 Terminated
Has Results
Ponatinib for Advanced Medullary Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention: Drug: Ponatinib
18 Recruiting Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Condition: Malignant Hepatobiliary Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Ponatinib Hydrochloride;   Other: Quality-of-Life Assessment
19 Recruiting Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Ponatinib
20 Recruiting Ponatinib in Advanced NSCLC w/ RET Translocations
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ponatinib

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Indicates status has not been verified in more than two years